Blocking a Sphingosine Receptor Relieves Pancreatic Cancer Pain by Suppressing CGRP Neuropeptide Signaling | Research

The takeaway

Blocking S1PR1 receptors in sensory nerve ganglia alleviated pancreatic cancer-associated neuropathic pain in mice by suppressing CGRP and TRPV1 upregulation, while also partially inhibiting tumor progression.

Dual benefit
S1PR1 antagonist FTY720 both alleviated pancreatic cancer neuropathic pain (by suppressing CGRP and TRPV1) and showed partial anti-tumor activity in a mouse model

What the researchers found

In PDAC patients, S1PR1 levels in intrapancreatic nerves were significantly higher in those experiencing cancer-associated pain versus those without pain. In a mouse orthotopic pancreatic cancer model:

• S1PR1 was upregulated in dorsal root ganglia (DRGs) and colocalized with neurons and satellite glial cells

• Intrathecal injection of S1PR1 antagonists W146 and FTY720 effectively alleviated pain hypersensitivity

• Both antagonists suppressed the upregulation of TRPV1 (a pain-sensing ion channel) and CGRP (calcitonin gene-related peptide, a key pain-signaling neuropeptide)

• FTY720 additionally demonstrated partial anti-tumor effects on pancreatic cancer progression

The finding that S1PR1 blockade suppresses CGRP connects this sphingolipid pathway to the same neuropeptide signaling axis targeted by migraine therapies (anti-CGRP antibodies).

Why it matters

Pancreatic cancer pain is among the most severe of any cancer type and poorly controlled by existing therapies. Finding that S1PR1 drives this pain through CGRP and TRPV1 upregulation provides both a new therapeutic target and a mechanistic link to established pain pathways. FTY720 (fingolimod) is already FDA-approved for multiple sclerosis, potentially accelerating its repurposing for cancer pain management.

How the study worked

Combined human and mouse study. Human component: histopathological sections and pain data from surgically resected PDAC patients, with S1PR1 immunohistochemistry in intrapancreatic nerves. Mouse component: orthotopic transplantation of MT5 pancreatic cancer cells in C57BL/6J mice, with pain assessment via abdominal mechanical hyperalgesia, hunch scoring, and open-field tests. S1PR1 expression and localization were characterized in DRGs. S1PR1 antagonists (W146, FTY720) were administered intrathecally to test analgesic and anti-tumor effects.

What this study cannot tell us

The mouse model used orthotopic tumor transplantation rather than spontaneous cancer development, which may not fully replicate human disease progression. Intrathecal drug delivery is impractical for most patients. The human component was observational (correlation between S1PR1 levels and pain), not interventional. FTY720's immunosuppressive properties could be problematic in cancer patients. The anti-tumor effects were described as 'partial' without quantification in the abstract.

How to read the evidence

This study combines human observational data (S1PR1 correlation with pain) and preclinical interventional data (mouse model). While the translational approach strengthens the evidence, the therapeutic conclusions rest on animal experiments with intrathecal delivery. No human interventional data exist for this application.

When this study was published

Published in 2025, this is a very recent study at the frontier of cancer pain research. The S1PR1-CGRP connection in pancreatic cancer pain is a novel finding that will require validation and clinical testing.

The bigger picture

This study bridges sphingolipid biology with neuropeptide pain signaling, showing that S1PR1 drives cancer pain through CGRP — the same peptide targeted by anti-migraine antibodies like erenumab and galcanezumab. The dual pain-relieving and anti-tumor properties of S1PR1 blockade are particularly exciting for a cancer type where palliative care is often the primary treatment focus. FTY720's existing approval status could facilitate rapid clinical translation.

Questions still open

Could systemic FTY720 administration achieve the same pain relief as intrathecal delivery while maintaining anti-tumor effects?
Do anti-CGRP antibodies already approved for migraine have any efficacy in pancreatic cancer pain?
How does S1PR1-mediated CGRP upregulation in cancer pain compare mechanistically to CGRP's role in migraine?

Common questions

Why is pancreatic cancer pain so difficult to treat?

Pancreatic tumors often invade surrounding nerves (perineural invasion), causing severe neuropathic pain that doesn't respond well to standard painkillers. The pain involves complex nerve signaling pathways including neuropeptides like CGRP. This study found that a receptor called S1PR1 is elevated in the nerves of pancreatic cancer patients with pain, driving the upregulation of pain-signaling molecules.

What is CGRP's role in this type of cancer pain?

CGRP (calcitonin gene-related peptide) is a neuropeptide well known for its role in migraine but also involved in many types of pain. In this study, pancreatic cancer caused S1PR1 receptors in sensory ganglia to upregulate CGRP production, amplifying pain signals. Blocking S1PR1 suppressed CGRP levels and relieved pain, suggesting that the CGRP pathway is a key mediator of pancreatic cancer-associated neuropathic pain.

Read the original research

Targeting sphingosine-1-phosphate receptor 1 alleviates neuropathic pain associated with pancreatic ductal adenocarcinoma in mice and inhibits tumor progression.

Molecular pain, 21, 17448069251371549

View on PubMed ↗Publisher’s paper ↗

Citation

Cai, Shen-Quan; Zhang, Yi-Xuan; Wang, Chun; Gao, Yu; Wang, Ting-Yu; Xu, Fang-Ning; Liu, Qing-Zheng; Yin, Jing; Zhang, Zhi-Jie; Zhang, Shu; Duan, Muan-Lin; Huang, Ying; Tao, Gao-Jian. (2025). Targeting sphingosine-1-phosphate receptor 1 alleviates neuropathic pain associated with pancreatic ductal adenocarcinoma in mice and inhibits tumor progression.. Molecular pain, 21, 17448069251371549. https://doi.org/10.1177/17448069251371549